# China Gamma Knife Market > China Gamma Knife Market Research Report: Size, Share, Trend Analysis By Disease Indication (Brain Metastasis, Cancer, Arteriovenous Malformation, Trigeminal Neuralgia, Others) and By Anatomy (Head, Neck, Others) - Growth Outlook & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 4.84% - **2024:** $ 41.82 Million - **2025:** $ 43.84 Million - **2035:** $ 70.32 Million - **Key Players:** Elekta AB (SE), Accuray Incorporated (US), Varian Medical Systems (US), Brainlab AG (DE), MediTech (US), Shenzhen Huikang Medical Technology Co (CN), Nico Corporation (US), Stereotactic Radiosurgery (US) **Report ID:** MRFR/HC/50659-HCR · **Pages:** 200 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** March 02, 2026 **URL:** https://www.marketresearchfuture.com/reports/china-gamma-knife-market-52417 --- ## Market Summary ## **China Gamma Knife Market Overview** As per MRFR analysis, the China Gamma Knife Market Size was estimated at 39.92 (USD Million) in 2024.The China Gamma Knife Market Industry is expected to grow from 45(USD Million) in 2025 to 78 (USD Million) by 2035. The China Gamma Knife Market CAGR (growth rate) is expected to be around 5.128% during the forecast period (2025 - 2035) **Key China Gamma Knife Market Trends Highlighted** The China Gamma Knife Market is experiencing notable growth, driven primarily by the increasing prevalence of brain-related disorders such as tumors and neurological conditions. As more health facilities incorporate advanced radiotherapy technologies, there is an evident trend towards Non-invasive treatment options in the market. This aligns with China's broader healthcare reforms aimed at enhancing patient care and outcomes.  Moreover, the Chinese government prioritizes the integration of innovative medical technologies to improve the healthcare system. This creates substantial opportunities for local manufacturers and international players to collaborate and enhance service offerings in the market.Recent trends indicate a shift towards personalized treatment approaches and improved patient access to Gamma Knife technologies due to expansions in healthcare infrastructure, especially in urban areas.  The rise of telemedicine and digital health tools is also influencing the market, allowing more patients to receive consultations and treatment from specialists without geographical limitations. Furthermore, ongoing research and development initiatives in China encourage the innovation of Gamma Knife technologies, enhancing efficacy and safety, thus attracting more healthcare facilities to adopt these advanced systems.  Additionally, there is a growing emphasis on training healthcare professionals in utilizing Gamma Knife systems effectively.Educational programs supported by hospitals and medical institutions are vital to ensuring that clinicians are equipped with the necessary skills for optimal patient care.  In summary, the China Gamma Knife Market is characterized by a combination of technological advancements, a focus on patient-centric care, and efforts to increase access to high-quality treatments, highlighting a rapidly evolving landscape that aims to meet the needs of patients across the country. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **China Gamma Knife Market Drivers** **Increasing Incidence of Cancer in China** The growing prevalence of cancer in China is a significant driver for the China Gamma Knife Market Industry. According to the National Cancer Center of China, cancer cases have doubled over the past two decades, with an estimated 4.57 million new cases reported in 2020 alone. This alarming trend is expected to escalate further, as the Chinese population ages and lifestyle changes contribute to increased risk factors.  Organizations such as the Chinese Society of Clinical Oncology are actively raising awareness and promoting advanced treatment options, including Gamma Knife Radiosurgery, which is becoming an increasingly preferred method for treating certain types of tumors and cancers due to its non-invasive nature and precision.As the demand for effective cancer treatment rises, the reliance on Gamma Knife technology is expected to grow accordingly in China, positioning the sector for robust growth. **Technological Advancements in Treatment Procedures** The rapid advancements in medical technology are transforming the landscape of cancer treatment in China and significantly influencing the China Gamma Knife Market Industry. Innovations such as improved imaging techniques and software enhancements in Gamma Knife systems enable healthcare professionals to perform complex procedures with greater accuracy and reduced side effects.  The Ministry of Health in China has been promoting the incorporation of advanced medical technologies in hospitals to enhance patient care.Also, Elekta and Varian, who control the Gamma Knife market, have developed systems that support intricate treatment protocols, which further entice healthcare facilities to adopt such technologies, consequently fostering increased investment in the market. **Growing Awareness and Acceptance of Stereotactic Radiosurgery** There is an increasing awareness and acceptance of stereotactic radiosurgery techniques among both healthcare professionals and patients in China, acting as a significant driver for the China Gamma Knife Market Industry. According to surveys conducted by various health organizations, more than 70% of oncologists in China acknowledge the efficacy of Gamma Knife treatments for specific cancers.  The efforts of the Chinese Alliance Against Cancer and other institutions have led to increased patient education regarding treatment options, which directly correlates to a higher incidence of patients seeking Gamma Knife procedures.Moreover, as patients become more informed about the benefits of non-invasive therapies vis-a-vis traditional surgical options, the demand for Gamma Knife treatments continues to rise, thereby stimulating market growth. **China Gamma Knife Market Segment Insights** **Gamma Knife Market Disease Indication Insights** The China Gamma Knife Market, specifically within the Disease Indication segment, is gaining considerable traction, owing to the increasing prevalence of neurological disorders and the growing need for precise treatment options. Among the various conditions treated with Gamma Knife technology, Brain Metastasis represents a significant portion of the market, as this condition often complicates cancer management and requires effective localized therapies to spare surrounding healthy tissues. The rise in cancer cases in China, bolstered by an aging population and lifestyle changes, further amplifies the demand for Gamma Knife procedures. Another pivotal area within this segment is Arteriovenous Malformation, a neurological condition that has seen increased awareness and early diagnosis, facilitating timely intervention through non-invasive radiosurgery methods. Meanwhile, Trigeminal Neuralgia is gaining recognition as a debilitating disorder often treated with Gamma Knife due to the efficacy and minimal recovery time associated with the procedure, offering considerable relief to patients. The 'Others' category encapsulates various diseases that could benefit from Gamma Knife treatment, indicating the broad applicability of this technology. In tandem, the rise of advanced imaging technologies and growing investment in healthcare infrastructure is fueling market potential, while the increasing burden of chronic diseases challenges healthcare resources, creating opportunities for innovative and effective treatment solutions. The China Gamma Knife Market is therefore likely to expand further, driven by ongoing research, favorable policies, and increasing patient awareness, which all contribute positively to the industry's trajectory. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **Gamma Knife Market Anatomy Insights** The China Gamma Knife Market, particularly focusing on the Anatomy segment, showcases a complex landscape critical to the treatment of various neurological conditions. This segment can be categorized into distinct areas such as Head, Neck, and Others, each playing a significant role in successful outcomes for patients. The Head segment is often regarded as the most prominent due to the prevalence of disorders like tumors and functional diseases targeted by Gamma Knife radiosurgery, further reinforced by advancements in technology that enhance precision and effectiveness. The Neck category, while less dominant, addresses specific challenges such as metastatic diseases and benign tumors, ensuring comprehensive treatment options for patients in this region. Other areas encompass a variety of anatomical considerations, broadening the scope for gamma knife applications, which may include cervical spine lesions and other critical regions. The ongoing growth of hospitals and specialized clinics across China, coupled with increased healthcare investment, serves to enhance the implementation of Gamma Knife procedures.  Overall, the China Gamma Knife Market segmentation in Anatomy is vital for addressing diverse therapeutic needs as it aligns with the country's commitment to improving healthcare services and adopting innovative medical technologies. **China Gamma Knife Market Key Players and Competitive Insights** The China Gamma Knife Market is characterized by intense competition and rapid technological advancements, significantly driven by the rising prevalence of neurological disorders and the increasing adoption of minimally invasive surgical techniques. As radiation therapy becomes a preferred choice for treating brain tumors and vascular malformations, various players are vying for market share by introducing innovative solutions tailored for the local healthcare landscape. The competitive dynamics encompass not only established players but also new entrants, which are aiming to capitalize on the growing demand for sophisticated treatment options.  This environment necessitates a comprehensive understanding of key competitors and their strategic initiatives to leverage opportunities in a market marked by both challenges and high growth potential.In the context of the China Gamma Knife Market, BrainLab holds a prominent position, leveraging its strong technological expertise and innovative approach to meet evolving customer needs. The company is noted for offering advanced software solutions that enhance the precision and efficiency of radiation therapy, thereby improving patient outcomes. BrainLab's unique strengths include its focus on integrating hardware and software systems, which optimize surgical workflows and facilitate better treatment planning.  The company has established a solid foothold in China by collaborating closely with local healthcare institutions and investing in comprehensive training programs for medical professionals. Such initiatives have not only strengthened its market presence but also fostered trust with stakeholders, thereby solidifying BrainLab's reputation in a competitive environment.Siemens Healthineers presents a robust profile within the China Gamma Knife Market through its innovative product portfolio that includes state-of-the-art imaging and therapy solutions.  The company has made significant strides in providing comprehensive solutions for precise targeted therapies, enhancing accuracy in Gamma Knife procedures. Siemens Healthineers has positioned itself effectively by prioritizing research and development, leading to pioneering advancements in non-invasive techniques tailored to the Chinese patient demographic. The company's strengths lie in its vast experience, reputation for quality, and strategic partnerships with local healthcare organizations.  Furthermore, Siemens Healthineers has actively engaged in mergers and acquisitions to bolster its market share and expand its capabilities within China. This strategy not only broadens its service offerings but also strengthens its competitive edge, allowing it to remain at the forefront of innovation in the Gamma Knife segment while addressing the specific needs of the Chinese healthcare market. **Key Companies in the China Gamma Knife Market Include** **China Gamma Knife Market Industry Developments** The China Gamma Knife Market has seen significant developments, particularly with major companies like BrainLab, Siemens Healthineers, NeuroLogica, and Elekta. Recently, in September 2023, Elekta announced an expansion in its partnerships with Chinese hospitals, aiming to enhance its service network and increase patient access to advanced radiosurgery technologies. Notably, on the acquisition front, in June 2023, Siemens Healthineers completed the acquisition of Varian Medical Systems, which is expected to strengthen its position in the radiation oncology market in China. In the last two years, the demand for Gamma Knife systems has grown due to increasing incidences of neurological disorders in China.  Shenzhen Mindray BioMedical Electronics reported substantial financial growth, indicating a strong market valuation boost in Q3 2023. The government's investment in healthcare technologies and radiotherapy is also driving innovations and providing a conducive environment for foreign investments, leading to more collaborations and joint ventures among the mentioned companies. Recent policies from health authorities emphasize the need for cutting-edge cancer treatment technologies, which position the businesses favorably for growth in the Chinese market. **China Gamma Knife Market Segmentation Insights** ## Market Drivers ### Increasing Incidence of Brain Disorders The rising prevalence of brain disorders in China is a crucial driver for the gamma knife market. Conditions such as brain tumors, arteriovenous malformations, and trigeminal neuralgia are becoming more common, leading to a heightened demand for effective treatment options. According to recent health statistics, the incidence of brain tumors in China has increased by approximately 20% over the past decade. This trend suggests that healthcare providers are increasingly turning to advanced technologies like gamma knife radiosurgery, which offers a non-invasive alternative to traditional surgical methods. The gamma knife market is likely to benefit from this growing patient population, as more individuals seek innovative solutions for their neurological conditions. ### Investment in Healthcare Infrastructure China's ongoing investment in healthcare infrastructure is significantly impacting the gamma knife market. The government has allocated substantial funds to enhance medical facilities, particularly in urban areas, where advanced treatment options are in high demand. Reports indicate that healthcare expenditure in China is projected to reach $1 trillion by 2025, with a significant portion directed towards advanced medical technologies. This investment is expected to facilitate the acquisition of gamma knife systems, thereby expanding access to cutting-edge treatment options. As hospitals and clinics upgrade their facilities, the gamma knife market is poised for growth, driven by the increasing availability of state-of-the-art medical equipment. ### Supportive Government Policies and Initiatives The Chinese government has implemented various policies aimed at promoting advanced medical technologies, including gamma knife systems. Initiatives to streamline the approval process for medical devices and provide financial incentives for healthcare facilities to adopt innovative treatments are becoming more prevalent. These supportive measures are expected to foster growth in the gamma knife market, as they encourage hospitals to invest in cutting-edge technologies. Additionally, government funding for research and development in the medical field may lead to further advancements in gamma knife applications. The gamma knife market is likely to thrive under these favorable conditions, as regulatory support enhances the overall landscape for medical innovation. ### Technological Innovations in Medical Equipment The gamma knife market is experiencing a surge in technological innovations that enhance treatment efficacy and patient outcomes. Recent advancements in imaging techniques and treatment planning software have improved the precision of gamma knife procedures. For instance, the integration of MRI and CT imaging allows for more accurate targeting of tumors, thereby minimizing damage to surrounding healthy tissue. This trend is particularly relevant in China, where the demand for high-quality medical equipment is on the rise. As hospitals invest in the latest gamma knife technologies, the market is likely to expand, driven by the need for improved treatment modalities that cater to the evolving healthcare landscape. ### Growing Awareness of Advanced Treatment Options There is a notable increase in public awareness regarding advanced treatment options for brain disorders in China. Educational campaigns and outreach programs have played a pivotal role in informing patients about the benefits of gamma knife radiosurgery. This growing awareness is likely to drive demand for the gamma knife market, as patients become more proactive in seeking non-invasive treatment alternatives. Furthermore, as healthcare professionals advocate for innovative therapies, the market is expected to witness a surge in patient referrals for gamma knife procedures. The gamma knife market stands to gain from this trend, as more individuals opt for advanced solutions to manage their health conditions. ## Future Outlook The [Gamma Knife Market](https://www.marketresearchfuture.com/reports/gamma-knife-market-19189) in China is projected to grow at a 4.84% CAGR from 2025 to 2035, driven by technological advancements and increasing healthcare investments. **New opportunities:** - Expansion of telemedicine services for remote consultations - Development of cost-effective gamma knife models for smaller hospitals - Partnerships with insurance providers to enhance reimbursement options By 2035, the gamma knife market is expected to achieve substantial growth and innovation. ## Segment Insights ### By Disease Indication: Brain Metastasis (Largest) vs. Cancer (Fastest-Growing) In the China gamma knife market, the distribution of market share across disease indications reveals that brain metastasis holds the largest share, reflecting its significant prevalence and demand for non-invasive treatment. Following closely is the cancer segment, which has shown remarkable growth, capturing the attention of healthcare providers and patients alike. Other segments, such as [arteriovenous malformation](https://www.marketresearchfuture.com/reports/arteriovenous-malformation-market-5092) and trigeminal neuralgia, hold smaller market shares but contribute to the overall diverse application of gamma knife technology. The growth trends within the disease indication segment are largely driven by advancements in technology and increased awareness of the benefits of gamma knife procedures. The cancer segment is particularly influenced by a rising incidence of different cancer types, as well as patients seeking targeted and efficient treatment options. As healthcare systems in China continue to adopt more sophisticated neurosurgical techniques, the market is expected to grow, with brain metastasis retaining dominance while cancer evolves as a growing focus area. Brain Metastasis (Dominant) vs. Cancer (Emerging) Brain metastasis is the dominant indication in the gamma knife market, characterized by its extensive patient base and the established efficacy of gamma knife radiosurgery in treating secondary brain tumors. Its recognized effectiveness in achieving tumor control with minimal side effects positions it as a preferred choice among clinicians and patients. Conversely, the cancer segment is emerging rapidly, propelled by the increasing burden of various cancer types and the demand for less invasive treatment alternatives. The growing prevalence of cancer, coupled with technological developments and better patient access to advanced therapies, supports the expanding use of gamma knife in treating a broader array of cancer conditions. ### By Anatomy: Head (Largest) vs. Neck (Fastest-Growing) In the China gamma knife market, the 'Head' segment holds the largest market share due to its extensive use in treating brain tumors and other neurological disorders. This segment has been instrumental in driving advancements in precision radiation therapy, overshadowing other segments. Conversely, the 'Neck' segment is gaining traction as a viable option for treating [head and neck cancers](https://www.marketresearchfuture.com/reports/head-and-neck-cancer-market-5798), capitalizing on increasing awareness and technological developments that enhance treatment effectiveness. As for growth trends, the 'Neck' segment is emerging as the fastest-growing area driven by rising incidences of throat and neck cancers. This trend is further supported by advancements in gamma knife technology that allow for improved targeting and reduced side effects, appealing to both clinicians and patients. The ongoing research and innovation in treatment modalities also contribute to the rapid growth of this segment. Head: Dominant vs. Neck: Emerging The 'Head' segment is characterized by its dominance in the China gamma knife market, primarily used for brain tumors, arteriovenous malformations, and functional disorders. This segment benefits from a well-established treatment protocol and recognized efficacy, making it the preferred choice for many healthcare providers. On the other hand, the 'Neck' segment is emerging with increasing adoption attributed to a rise in the diagnosis of neck-related cancers and a shift in treatment paradigms. Enhanced imaging technologies and treatment planning systems are making neck surgeries more common and effective. This growth reflects an expanding acceptance of gamma knife treatment beyond traditional applications, making it a competitive player in the overall market landscape. ## Competitive Benchmarking The gamma knife market in China is characterized by a competitive landscape that is increasingly shaped by innovation, strategic partnerships, and regional expansion. Key players such as Elekta AB (SE), Accuray Incorporated (US), and Shenzhen Huikang Medical Technology Co (CN) are actively pursuing strategies that enhance their market positioning. Elekta AB (SE) focuses on technological advancements in stereotactic radiosurgery, while Accuray Incorporated (US) emphasizes personalized treatment solutions. Shenzhen Huikang Medical Technology Co (CN) is leveraging local manufacturing capabilities to cater to the growing demand for affordable and effective treatment options. Collectively, these strategies contribute to a dynamic competitive environment, where companies are not only vying for market share but also striving to meet the evolving needs of healthcare providers and patients.In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance operational efficiency. The market structure appears moderately fragmented, with several players competing for dominance. This fragmentation allows for a diverse range of products and services, fostering innovation and driving competition. The collective influence of key players is significant, as they work to establish their presence in various regions while adapting to local market conditions. In October Elekta AB (SE) announced a strategic partnership with a leading Chinese hospital to enhance the accessibility of its gamma knife technology. This collaboration is expected to facilitate the integration of advanced treatment protocols, thereby improving patient outcomes. The strategic importance of this partnership lies in Elekta's ability to leverage local expertise and resources, which may enhance its competitive edge in the Chinese market. In September Accuray Incorporated (US) launched a new software platform designed to optimize treatment planning for gamma knife procedures. This innovation is anticipated to streamline workflows and improve the precision of treatments. The introduction of this platform underscores Accuray's commitment to technological advancement and positions the company favorably against competitors who may not have similar capabilities. In August Shenzhen Huikang Medical Technology Co (CN) expanded its product line to include a more cost-effective gamma knife model aimed at smaller healthcare facilities. This strategic move is likely to capture a broader customer base, particularly in underserved regions. By addressing the price sensitivity of certain market segments, Shenzhen Huikang may enhance its market share and establish itself as a key player in the competitive landscape. As of November current trends in the gamma knife market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI) in treatment planning and execution. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in enhancing technological capabilities and market reach. Looking ahead, competitive differentiation is expected to evolve, with a shift from price-based competition to a focus on innovation, advanced technology, and reliable supply chains. This transition may redefine how companies position themselves in the market, emphasizing the importance of delivering superior value through cutting-edge solutions. ## Recent News & Developments The China Gamma Knife Market has seen significant developments, particularly with major companies like BrainLab, Siemens Healthineers, NeuroLogica, and Elekta. Recently, in September 2023, Elekta announced an expansion in its partnerships with Chinese hospitals, aiming to enhance its service network and increase patient access to advanced radiosurgery technologies. Notably, on the acquisition front, in June 2023, Siemens Healthineers completed the acquisition of Varian Medical Systems, which is expected to strengthen its position in the radiation oncology market in China. In the last two years, the demand for Gamma Knife systems has grown due to increasing incidences of neurological disorders in China.  Shenzhen Mindray BioMedical Electronics reported substantial financial growth, indicating a strong market valuation boost in Q3 2023. The government's investment in healthcare technologies and radiotherapy is also driving innovations and providing a conducive environment for foreign investments, leading to more collaborations and joint ventures among the mentioned companies. Recent policies from health authorities emphasize the need for cutting-edge cancer treatment technologies, which position the businesses favorably for growth in the Chinese market. ## Report Scope | MARKET SIZE 2024 | 41.82(USD Million) | | --- | --- | | MARKET SIZE 2025 | 43.84(USD Million) | | MARKET SIZE 2035 | 70.32(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 4.84% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Elekta AB (SE), Accuray Incorporated (US), Varian Medical Systems (US), Brainlab AG (DE), MediTech (US), Shenzhen Huikang Medical Technology Co (CN), Nico Corporation (US), Stereotactic Radiosurgery (US) | | Segments Covered | Disease Indication, Anatomy | | Key Market Opportunities | Advancements in precision targeting technologies enhance treatment efficacy in the gamma knife market. | | Key Market Dynamics | Rising demand for advanced cancer treatments drives innovation and competition in the gamma knife market. | | Countries Covered | China | ## Frequently Asked Questions **Q: What was the overall market valuation of the China gamma knife market in 2024?** A: The overall market valuation was $41.82 Million in 2024. **Q: What is the projected market valuation for the China gamma knife market by 2035?** A: The projected market valuation for 2035 is $70.32 Million. **Q: What is the expected CAGR for the China gamma knife market during the forecast period 2025 - 2035?** A: The expected CAGR for the market during 2025 - 2035 is 4.84%. **Q: Which companies are considered key players in the China gamma knife market?** A: Key players include Elekta AB, Accuray Incorporated, Varian Medical Systems, and others. **Q: What segment had the highest valuation in the disease indication category in 2024?** A: In 2024, the Cancer segment had the highest valuation at $25.0 Million. **Q: What is the valuation range for the Trigeminal Neuralgia segment in 2024?** A: The valuation range for the Trigeminal Neuralgia segment was $5.0 Million to $8.0 Million. **Q: How does the valuation of the Brain Metastasis segment compare to others in 2024?** A: The Brain Metastasis segment ranged from $10.0 Million to $17.0 Million, indicating a moderate performance. **Q: What was the valuation for the Neck anatomy segment in 2024?** A: The Neck anatomy segment had a valuation range of $10.0 Million to $15.0 Million in 2024. **Q: What is the projected growth for the Others segment in the anatomy category by 2035?** A: The Others segment is projected to grow to a valuation range of $16.82 Million to $30.32 Million by 2035. **Q: What does the market data suggest about the future of the China gamma knife market?** A: The market data suggests a steady growth trajectory, with increasing valuations expected through 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/china-gamma-knife-market-52417*